Autologous CIK Cells Infusion for the Treatment of Lung Cancer: a Randomized Controlled Study

Primary lung cancer diagnosis (including small cell lung cancer, lung adenocarcinoma, lung squamous cell carcinoma and large cell carcinoma) patients

Inclusion Criteria:

• 18~70 year old, KPS score >50 points, estimate survival > 3 months;
• Primary lung cancer patients after chemotherapy or radiation therapy;
• Primary lung cancer patients after targeted therapy;
• Primary lung cancer patients with lung function can not accept operation or unwilling to operation;
• Primary lung cancer recurrence or surgery can't complete resection;
• Primary lung cancer patients after intervention therapy(I125 implanted, freezing, rf, etc.);
• No serious mental illness and no serious heart, liver, kidney diseases, unincorporated other potentially lethal diseases;
• Patients Voluntary attempt, and informed consent.

Exclusion Criteria:

• History of cardiovascular disease: congestive heart failure > New York heart association (NYHA) level II, unstable angina patients (resting when the angina symptoms) or new happen angina pectoris (recent 3 months) or recent 6 months of myocardial infarction;
• Cachexia; or other deadly diseases;
• Liver function laboratory ALT, AST more than normal limits on 2.0 times ; Or kidney TBIL, BUN more than normal limits on 1.0 times , or Cr more than normal upper limit;
• Active infection;
• Pregnant or lactating women
• At present Is receiving other cancer treatment (such as chemotherapy, radiation therapy, chemotherapy, immunosuppressants and thrombosis, targeted agents);
• Now or recently will join another experimental clinical study ;
• Other situations that the researchers considered unsuitable for this study (such as mental illness, drug abuse, HIV infections, etc.), or influence on the results of clinical trials for analysis.